mm1313亚洲精品,欧美俄罗斯40老熟妇,欧美日韩在线观看视频在线,亚洲欧美国产激情综合在线

掃碼關(guān)注公眾號(hào)           掃碼咨詢(xún)技術(shù)支持           掃碼咨詢(xún)技術(shù)服務(wù)
  
客服熱線:400-901-9800  客服QQ:4009019800  技術(shù)答疑  技術(shù)支持  質(zhì)量反饋  人才招聘  關(guān)于我們  聯(lián)系我們
国产亚洲欧美日韩综合一区二区,欧美日韩亚洲欧美精品专区,欧美人体一区二区三区
首頁(yè) > 產(chǎn)品中心 > 一抗 > 產(chǎn)品信息
Mouse Anti-AR/Androgen receptor  antibody (bsm-34141M)  
~~~促銷(xiāo)代碼KT202411~~~
訂購(gòu)熱線:400-901-9800
訂購(gòu)郵箱:sales@www.p2b3.cn
訂購(gòu)QQ:  400-901-9800
技術(shù)支持:techsupport@www.p2b3.cn
說(shuō)明書(shū): 50ul  100ul  
50ul/1180.00元
100ul/1980.00元
大包裝/詢(xún)價(jià)

產(chǎn)品編號(hào) bsm-34141M
英文名稱(chēng) Mouse Anti-AR/Androgen receptor  antibody
中文名稱(chēng) 雄激素受體(AR)單克隆抗體
別    名 Androgen receptor isoform 2; AIS; AIS; ANDR_HUMAN; Androgen receptor (dihydrotestosterone receptor; testicular feminization; spinal and bulbar muscular atrophy; Kennedy disease); Androgen receptor; AR; DHTR; Dihydro Testosterone Receptor; Dihydrotestosterone receptor; HUMARA; HYSP1; HYSP1; KD; NR3C4; Nuclear receptor subfamily 3 group C member 4; SBMA; SMAX1; Spinal and bulbar muscular atrophy; TFM; .  
抗體來(lái)源 Mouse
克隆類(lèi)型 Monoclonal
克 隆 號(hào) 8B7
交叉反應(yīng) Human
產(chǎn)品應(yīng)用 IHC-P=1:100-500,IHC-F=1:100-500,IF=1:100-500
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
理論分子量 99kDa
細(xì)胞定位 細(xì)胞核 
性    狀 Liquid
濃    度 1mg/ml
免 疫 原 KLH conjugated synthetic peptide derived from human Androgen Receptor 
亞    型 IgG2b/Kappa
純化方法 affinity purified by Protein A
緩 沖 液 Liquid in PBS containing, 0.5% BSA and 0.02% Proclin300.
保存條件 Store at 4℃ for one year.
注意事項(xiàng) This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
PubMed PubMed
產(chǎn)品介紹 The androgen receptor gene is more than 90 kb long and codes for a protein that has 3 major functional domains: the N-terminal domain, DNA-binding domain, and androgen-binding domain. The protein functions as a steroid-hormone activated transcription factor. Upon binding the hormone ligand, the receptor dissociates from accessory proteins, translocates into the nucleus, dimerizes, and then stimulates transcription of androgen responsive genes. This gene contains 2 polymorphic trinucleotide repeat segments that encode polyglutamine and polyglycine tracts in the N-terminal transactivation domain of its protein. Expansion of the polyglutamine tract causes spinal bulbar muscular atrophy (Kennedy disease). Mutations in this gene are also associated with complete androgen insensitivity (CAIS). Two alternatively spliced variants encoding distinct isoforms have been described. [provided by RefSeq, Jul 2008]

Function:
Steroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Transcription factor activity is modulated by bound coactivator and corepressor proteins. Transcription activation is down-regulated by NR0B2. Activated, but not phosphorylated, by HIPK3 and ZIPK/DAPK3.

Subunit:
Binds DNA as a homodimer. Part of a ternary complex containing AR, EFCAB6/DJBP and PARK7. Interacts with HIPK3 and NR0B2 in the presence of androgen. The ligand binding domain interacts with KAT7/HBO1 in the presence of dihydrotestosterone. Interacts with EFCAB6/DJBP, PELP1, PQBP1, RANBP9, RBAK, SPDEF, SRA1, TGFB1I1, ZNF318 and RREB1. Interacts with ZMIZ1/ZIMP10 and ZMIZ2/ZMIP7 which both enhance its transactivation activity. Interacts with SLC30A9 and RAD54L2/ARIP4 (By similarity). Interacts via the ligand-binding domain with LXXLL and FXXLF motifs from NCOA1, NCOA2, NCOA3, NCOA4 and MAGEA11. The AR N-terminal poly-Gln region binds Ran resulting in enhancement of AR-mediated transactivation. Ran-binding decreases as the poly-Gln length increases. Interacts with HIP1 (via coiled coil domain). Interacts (via ligand-binding domain) with TRIM68. Interacts with TNK2. Interacts with USP26. Interacts with RNF6. Interacts (regulated by RNF6 probably through polyubiquitination) with RNF14; regulates AR transcriptional activity. Interacts with PRMT2 and TRIM24. Interacts with GNB2L1/RACK1. Interacts with RANBP10; this interaction enhances dihydrotestosterone-induced AR transcriptional activity. Interacts with PRPF6 in a hormone-independent way; this interaction enhances dihydrotestosterone-induced AR transcriptional activity. Interacts with STK4/MST1. Interacts with ZIPK/DAPK3. Interacts with LPXN. Interacts with MAK. Part of a complex containing AR, MAK and NCOA3.

Tissue Specificity:
Isoform 2 is mainly expressed in heart and skeletal muscle.

DISEASE:
Defects in AR are the cause of androgen insensitivity syndrome (AIS) [MIM:300068]; previously known as testicular feminization syndrome (TFM). AIS is an X-linked recessive form of pseudohermaphroditism due end-organ resistance to androgen. Affected males have female external genitalia, female breast development, blind vagina, absent uterus and female adnexa, and abdominal or inguinal testes, despite a normal 46,XY karyotype.
Defects in AR are the cause of spinal and bulbar muscular atrophy X-linked type 1 (SMAX1) [MIM:313200]; also known as Kennedy disease. SMAX1 is an X-linked recessive form of spinal muscular atrophy. Spinal muscular atrophy refers to a group of neuromuscular disorders characterized by degeneration of the anterior horn cells of the spinal cord, leading to symmetrical muscle weakness and atrophy. SMAX1 occurs only in men. Age at onset is usually in the third to fifth decade of life, but earlier involvement has been reported. It is characterized by slowly progressive limb and bulbar muscle weakness with fasciculations, muscle atrophy, and gynecomastia. The disorder is clinically similar to classic forms of autosomal spinal muscular atrophy. Note=Caused by trinucleotide CAG repeat expansion. In SMAX1 patients the number of Gln ranges from 38 to 62. Longer expansions result in earlier onset and more severe clinical manifestations of the disease.
Note=Defects in AR may play a role in metastatic prostate cancer. The mutated receptor stimulates prostate growth and metastases development despite of androgen ablation. This treatment can reduce primary and metastatic lesions probably by inducing apoptosis of tumor cells when they express the wild-type receptor.
Defects in AR are the cause of androgen insensitivity syndrome partial (PAIS) [MIM:312300]; also known as Reifenstein syndrome. PAIS is characterized by hypospadias, hypogonadism, gynecomastia, genital ambiguity, normal XY karyotype, and a pedigree pattern consistent with X-linked recessive inheritance. Some patients present azoospermia or severe oligospermia without other clinical manifestations.

Similarity:
Belongs to the nuclear hormone receptor family. NR3 subfamily.
Contains 1 nuclear receptor DNA-binding domain.

SWISS:
P10275

Gene ID:
367

Database links:

Entrez Gene: 367 Human


Entrez Gene: 11835 Mouse


Entrez Gene: 24208 Rat


Omim: 313700 Human


SwissProt: P10275 Human


SwissProt: P19091 Mouse


SwissProt: P15207 Rat


Unigene: 496240 Human


Unigene: 39005 Mouse


Unigene: 394224 Mouse


Unigene: 439657 Mouse


Unigene: 9813 Rat



產(chǎn)品圖片
Paraformaldehyde-fixed, paraffin embedded (human breast carcinoma); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Incubation with (AR/Androgen receptor) Monoclonal Antibody, Unconjugated (bsm-34141M) at 1:10 overnight at 4°C, followed by operating according to SP Kit(Mouse)(sp-0024) instructionsand DAB staining.
Paraformaldehyde-fixed, paraffin embedded (human Prostate Tumor); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Incubation with (AR/Androgen receptor) Monoclonal Antibody, Unconjugated (bsm-34141M) at 1:10overnight at 4°C, followed by operating according to SP Kit(Mouse)(sp-0024) instructionsand DAB staining.
版權(quán)所有 2004-2026 www.www.p2b3.cn 北京博奧森生物技術(shù)有限公司
通過(guò)國(guó)際質(zhì)量管理體系ISO 9001:2015 GB/T 19001-2016    證書(shū)編號(hào): 00124Q34771R2M/1100
通過(guò)國(guó)際醫(yī)療器械-質(zhì)量管理體系ISO 13485:2016 GB/T 42061-2022    證書(shū)編號(hào): CQC24QY10047R0M/1100
京ICP備05066980號(hào)-1         京公網(wǎng)安備110107000727號(hào)
花垣县| 鲁山县| 黑龙江省| 许昌县| 乐陵市| 曲麻莱县| 甘德县| 泌阳县| 皋兰县| 郴州市| 嘉兴市| 沈阳市| 东兰县| 出国| 长岛县| 东乌| 西乌珠穆沁旗| 金秀| 镇巴县| 黄陵县| 淮安市| 盐津县| 日喀则市| 岑溪市| 临朐县| 东乡县| 宁津县| 河南省| 大姚县| 通州区| 阿图什市| 曲周县| 霍城县| 攀枝花市| 临西县| 和龙市| 乌苏市| 诏安县| 丽水市| 浦北县| 梁平县|